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ABSTRACT  
Periprosthetic joint infection (PJI) is a significant and costly challenge to the orthopedic 
community. The lack of a gold standard for diagnosis remains the biggest obstacle in the 
detection and subsequent treatment of PJI. Molecular markers in the serum and joint fluid 
aspirate hold immense promise to enhance the development of a firm diagnostic criterion. The 
primary goal is one marker with high sensitivity and specificity. Here, we review our current 
research efforts in the field of molecular markers: specifically, C-reactive protein, erythrocyte 
sedimentation rate, white blood cells, and leukocyte esterase. Each marker has been studied to 
determine its sensitivity, specificity, and positive and negative predictive values in diagnosing 
PJI.  
KEY WORDS: Periprosthetic join infection, Joint arthroplasty, C-reactive protein, Leukocyte 
esterase, Synovial fluid aspirate 
 
 
 
 
Introduction 
Periprosthetic joint infection (PJI) poses a significant challenge to the orthopedic community. As 
the number of joint replacement surgeries in the United States continues to climb, so does the 
threat of infection associated with these operations. PJI has a prevalence of 1% to 4% after 
primary total knee arthroplasty (TKA) (1-4)  and 1% to 2% after primary total hip arthroplasty 
(THA) (5, 6). At our institution, infection remains the most common cause of failure of total 
joint arthroplasty (TJA). As indicated by our institutional database of 20,046 hips and knee 
arthroplasties, 3.7% of patients required re-operation with infection as the leading cause.  
The major dilemma facing the orthopedic community remains the absence of a gold 
standard for the diagnosis of PJI (7). Currently, a large number of tests are available and many 
are used in combination. Studies that aim to assess the value of each of these tests individually 
calculate their sensitivity, specificity, or accuracy in the detection of infection and most 
commonly utilize either intraoperative culture, histology results, or a combination of these 
parameters as the reference criterion for a comparison in diagnosis (8-13). The rate of false 
positives (5-37%) (2, 14-18) and false negatives (2-18%) (19-23) of tissue and fluid culture 
decreases their accuracy in the diagnosis of PJI. A new standard that is accurate and efficient is 
needed in order to minimize a delay in diagnosis, prevent misdiagnosis, and provide the best 
treatment option in each case.  
Ambiguous diagnosis in PJI cases creates significant psychological stress for both 
patients and surgeons looking for the best treatment options for these revision arthroplasty cases. 
Moreover, the financial burden of a revision arthroplasty is increased when the revision 
operation is for PJI, as these cases are estimated to cost $60,000 more than mechanical revisions 
(24). Revisions associated with infection can lead to a higher number of hospitalizations, more 
days in the hospital, more operations, more outpatient visits, and also increased outpatient 
charges compared to revisions associated with mechanical failure (24).  
Proper surgical planning for revision arthroplasty relies not only on an accurate 
diagnosis of infected joints, but also on isolation of the causative organism, as treatment varies 
accordingly. The issue of antibiotic resistance is of considerable concern due to the increase in 
PJI cases caused by resistant organisms. There is a higher cost associated with the treatment of 
infections with methicillin-resistant organisms. The cost of antibiotic resistance averages 
$107,264 per case versus $68,053 in each PJI case caused by non-resistant strains (24). Surgeons 
at the Rothman Institute have long been focused on the challenges of PJI, and have implemented 
an extensive strategy in order to combat these issues on several fronts. Discovery and utilization 
of molecular markers that can serve as a diagnostic tool in PJI has become the aim of research. 
The development of firm diagnostic criteria in order to properly identify and treat periprosthetic 
joint infections remains paramount. 
 
CHALLENGES OF PERIPROSTHETIC JOINT INFECTION 
 
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) analyses are currently 
utilized in many orthopedic practices as standard serology tests aimed at assessing joint 
infection. In 2009, threshold levels, with optimal sensitivity and specificity, were determined that 
significantly aided the clinical diagnosis of infection in hip revision cases. Based on available 
literature, this was the first study of its kind to statistically determine an ideal cut-off value for 
ESR and CRP. Patients in this study were diagnosed with PJI if they met our institutional criteria 
for the diagnosis of infection. Using our infection database at the Rothman Institute, serology 
data was retrospectively collected and examined for ESR and CRP in 479 patients (26.5% 
infected). Of the infected population, 28% underwent irrigation and debridement with retention 
of components, 48% required two-stage resection arthroplasty for underlying infection, and 13% 
received a one-stage reimplantation (25). The remaining 11% were patients who were later 
diagnosed as infected after an original revision for mechanical failure.  
In order to assess the accuracy of ESR and CRP tests in the diagnosis of PJI, receiver 
operating-characteristic curves (ROC) were calculated for each test. ROC allows for a 
visualization of the relationship between true-positives (sensitivity) and false-positives (1-
specificity). Area under the curve (AUC) is determined and is considered a measurement of 
accuracy for each test. An AUC equal to 1 denotes 100% sensitivity and specificity, or an ideal 
test. An AUC > 0.9 is considered an excellent test, while an AUC < 0.5 is less helpful (25). In 
order to determine the diagnostic cut off levels of ESR and CRP, values corresponding to the 
points on the ROC curves nearest the upper left hand corner of the graph were chosen to 
establish an optimal balance between sensitivity and specificity in diagnosing PJI. These values 
were determined to be 31 mm/h (ESR) and 20.5 mg/l (CRP) (25) (Fig 1).  
The next phase involved evaluation and comparison of sensitivity, specificity, positive 
and negative predictive values for cut-offs frequently used in literature (30 mm/h ESR and 10 
mg/l CRP) with ROC-determined cut-off values (31 mm/h ESR and 20.5 mg/l CRP). When 
using the ROC-determined cut-off value of the two tests in combination (either/or scenario), we 
were able to improve sensitivity and negative likelihood ratio compared to both tests being used 
separately (Tab. I, Fig. 1). The overall success rate increases when the two tests are used in 
combination as the rate of false negatives from misdiagnosed cases drops to 2.7%. 
 
TABLE I- USE OF CUT-OFF VALUES 
ARBITRARILY CHOSEN FROM 
LITERATURE TO DETERMINE 
QUALITY OF DIAGNOSTIC TESTS FOR 
ESR AND CRP 
 
 
  
 
 
 
 
 
 
 
 
Fig. 1 - Receiver operating-characteristic curves for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).  
 
ESTABLISHMENT OF A DIAGNOSTIC CRITERION 
After statistically defining ESR and CRP cut-off values, research efforts were focused on 
utilizing molecular diagnostics to create a diagnostic criterion for PJI. In a retrospective study, 
data was collected on 172 revision TKA cases at our institution between April 2002 and 
November 2009. These cases were used to evaluate the variation among six published sets of 
diagnostic criterion, which was then compared to a newly proposed set of criteria (8¬12, 26). 
Overall, there were 41 cases (24%) where infection diagnosis conflicted between studies (27). 
According to the proposed new diagnostic criteria, PJI was suspected when one of the four 
parameters listed in Table II showed a positive result.  
The results of our study showed an infected/uninfected ratio of 92/80. There was a large 
variance in sensitivity (54¬100%), specificity (39-100%), and accuracy (53-100%) when 
referenced against each of the previously established criterion (27). Interestingly, five cases were 
identified as infected by our proposed criteria while at least 4 of the existing sets had labeled it as 
uninfected. These five cases were culture negative and had no observed purulence or sinus tract 
intraoperatively. They were only diagnosed as infected because of elevated molecular markers 
from serum or synovial fluid. Three of these five had other complicating inflammatory or 
systemic issues (sickle cell anemia, chronic renal failure, and systemic lupus erythematosus) that 
contributed to the elevated levels. One of these five received a subsequent irrigation and 
debridement for wound dehiscence and he-matoma 2 weeks after revision. This patient’s wound 
failed to close, and had a hematoma and necrotic tissue in superficial and deep tissue with no 
purulence and negative cultures. The last patient received an 8-week course of antibiotics and 
lifetime oral antibiotics due to coagulase-negative Staphylococcus growth in broth from 
preoperative joint fluid and intraoperative joint fluid during a revision to a total femur 
replacement. After 1 year follow-up this patient still had elevated ESR and CRP but reported no 
complications (27).   
Table II - PROPOSED NEW DIAGNOSTIC CRITERIA  
Periprosthetic Infection is present if one of the following four criteria are present:  
1) Draining sinus tract  
2) Positive culture on solid medium (>5 colonies)  
3) Purulence seen intraoperatively  
4) Three abnormal values out of following four:  
a) ESR ≥ 30 mm/hr (serum)     
b) C-reactive proteins ≥ 1 mg/dL (serum)     
c) WBC > 1,760 cells/ µl for acute PJI or 10,700 cells/ µl for chronic PJI (aspirate)     
d) Neutrophil percentage > 73% for chronic PJI or > 89% for acute PJI (aspirate)  
 
The discrepancy between definitions of infection serves to highlight the importance of 
preoperative identification of PJI using our new criteria. In order to properly plan and treat 
revision patients, specific and firm universal criteria must be put in place. We believe that a 
common set of diagnostic criteria that accounts for aspirate analysis will improve the treatment 
of PJI.  
Shortcomings of available tests for the diagnosis of PJI motivated members of the 
orthopedic community to focus research efforts on the development of more accurate diagnostic 
criteria. Most tests are either expensive (radiology scans), subjective in their interpretation 
(frozen sections), not specific enough (ESR/CRP/WBC counts in serum), or simply time-
consuming (culture). In December of 2010, a collaboration between several orthopedic 
institutions across the country resulted in the establishment of an official working guideline for 
PJI. This algorithm will be a work in progress as the findings of various investigations allow for 
a more specific tool to increase efficiency and accuracy of diagnosis. 
 
MOLECULAR MARKERS: RECENT ADVANCEMENTS IN PJI 
Serum ESR and CRP first showed promise as molecular markers for diagnosis of PJI. However, 
exploration of these and other markers in the synovial fluid became the focus of research efforts 
aimed at finding a more specific diagnostic modality. At the Rothman Institute, synovial fluid 
samples were prospectively collected from 74 cases of revision hip or knee arthroplasty for 
septic or aseptic failure (28). Samples were shipped in bulk to Rules-Based Medicine (RBM) 
(Austin, TX) in order to detect and quantify the concentration of 46 inflammatory proteins in 
each sample. RBM assayed our samples according to their Human Inflammation Multi-analyte 
Profiling (MAP) protocols using a multiplex ELISA assay. To determine whether or not these 
samples were infected, the aforementioned institutional diagnostic criteria were used to classify 
each case. Thirty-one samples were classified as infected (41.9%) and 43 as not infected (58.1%) 
according to these criteria (28). Receiver operating characteristic (ROC) curves were used to 
investigate sensitivity, specificity, and determine the diagnostic value of each protein marker. 
The analysis of these 74 samples yielded 18 proteins with AUC > 0.7 which denotes at least fair 
diagnostic value (Tab. III).  
Identifying these anti-inflammatory proteins brings to light two important results. First, 
inflammatory proteins can be found in the synovial fluid in appreciable and quantifiable 
concentrations. Second, the variable level of concentrations of these markers parallels the 
presence or absence of PJI (28). The results of this study confirmed several similar conclusions 
regarding infection-related biomarkers in a recent study by Deirmengian et al (29) which used 
different immunoassays and methods to investigate 17 similar biomarkers. A fair comparison of 
only 6 proteins could be established and IL-6 bore the most significant link to infected cases. The 
promising results obtained from the analysis of Rules Based Medicine’s multiplex ELISA further 
focused research goals on investigation of those five proteins with AUC > 0.9.  
 
MOLECULAR MARKERS IN SYNOVIAL FLUID  
Several studies have taken a closer look at synovial fluid for biomarkers in PJI. Each study 
proposed slightly varying cut off values for normal ranges of ESR, CRP, WBC, or PMN% (31-
33). This was the impetus for our multi-institutional collaborative effort with Rush University 
Medical Center (Chicago, IL, USA) and The Center for Adult Joint Reconstruction (Newton, 
MA, USA) aimed to investigate specific inflammatory markers for PJI in synovial fluid and 
resulted in a Mark Coventry Award publication. A retrospective review was conducted of 11,964 
primary TKAs performed on 9,826 patients at these institutions between April 1999 and 
December 2008. Of the 146 cases identified as having received a knee aspiration within 6 weeks 
of surgery, there were 19 cases classified as infected due to positive cultures or gross purulence 
(30). Each sample was evaluated for white blood cell (WBC) count and differential as well as 
CRP and/or ESR levels in order to classify infected from non-infected cases.  
The results of this collaborative cohort indicate a significantly elevated difference 
between the infected group compared to the noninfected group for synovial WBC count (p 
<0.0001), PMN% (p=0.0314), and CRP values (p=0.0042). No significant difference in ESR 
levels was found between the two cohorts (p=0.4626) (30) (Tab. IV). Ultimately, this study 
showed the diagnostic value of synovial WBC as a reliable marker for PJI during the early 
postoperative period. 
C-REACTIVE PROTEIN (CRP) 
Ongoing efforts aimed at finding a gold standard diagnostic test have brought great attention to 
CRP in synovial fluid. This promising biomarker has potential to serve as a low-cost diagnostic 
tool for PJI. CRP is a common serology test that is easily analyzed under routine hospital 
laboratory conditions.  
RBM analysis of CRP showed a threshold level of 3.605 mg/l in synovial fluid analysis 
with a sensitivity of 87.1%, specificity of 97.7%, PPV of 96.4%, NPV of 91.5% and an accuracy 
of 93.3% (28). Based on this data, our goal was to investigate whether the accuracy of standard 
CRP assay for detection of PJI could be improved by measuring CRP in synovial fluid. Synovial 
fluid specimens were collected in the operating room before arthroplasty from 72 cases of 
revision total knee arthroplasty in order to calculate the concentration of synovial CRP to 
determine the sensitivity, specificity, PPV, and NPV (34). These samples were all labeled and 
classified as infected or uninfected based on our institutional criteria for diagnosis of PJI. All 72 
(29 infected, 43 uninfected) samples that were sent to RBM to be run on a multiplex 
immunoassay platform and 15 samples were also analyzed using CRP ELISA kit (10 infected 
and 5 uninfected) (GenWay Biotech, San Diego, CA, USA). All preoperative serum CRP 
samples (68 samples; 29 infected, 39 uninfected) were analyzed by review of data from hospital 
records. For each assay, sensitivity, specificity, and ROC curve analyses was generated using our 
institutional diagnostic criteria (34) (Tab. V).  
The findings of this study indicate that CRP concentrations in the synovial fluid rather 
than in blood serum improves the diagnostic accuracy of this test in identifying PJI, making CRP 
a promising biomarker in this field. The results spurred further study of CRP using larger sample 
sizes as well as the expansion of the current cohort to include patients with failed hip 
arthroplasties. In our prospective study, synovial fluid samples collected from patients 
undergoing primary and revision TJA are investigated for any correlation between synovial and 
serum CRP levels as well as white blood cell count and differential. Interim analysis of 97 
synovial fluid samples from 97 patients, 33 diagnosed with PJI and 64 not infected, shows 
statistically significant differences between the groups for serum CRP, synovial fluid CRP, ESR, 
synovial WBC count, and neutrophil differential (p<0.001). The mean aseptic synovial fluid 
CRP value was 1.64 mg/l while the mean septic synovial fluid CRP value was 46.27 mg/l 
(p<0.0001). An ROC curve shows 84.8% sensitivity, 95.5% specificity, at a CRP synovial fluid 
threshold of 9.5 mg/l and an AUC of 0.93. Although this data is not finalized, we are hopeful that 
CRP will continue to show promise for the development of a quick, easy, and low-cost molecular 
diagnostic tool. 
 
 
LEUKOCYTE ESTERASE: A POTENTIAL DIAGNOSTIC TOOL 
One of the most exciting molecular markers we are working on is leukocyte esterase (LE). We 
hypothesized that neturophils recruited into an infected joint would release LE and its presence 
would suggest PJI. Between May of 2007 and April of 2009, the following two study cohorts 
were evaluated: (i) 108 patients (30 infected, 78 uninfected) undergoing revision TKA at the 
Rothman Institute, for whom aspirations were done intraoperatively, just prior to arthrotomy; and 
(ii) 17 (5 infected, 12 uninfected) patients undergoing a PJI workup with knee aspirations 
collected at the time of the clinic visit (35). All patients were classified as infected/uninfected 
based on the previously discussed, newly proposed institutional criteria.  
In order to measure the LE presence in joint fluid, a standard chemical test strip that 
contained seven reagent pads: pH, glucose, ketones, protein, nitriles, and blood was used (Roche 
Chemstrip ®7 Urine Test Strip, Roche Diagnostics, Indianapolis, IN, USA). The colorimetric 
change in LE reagent pad occurs via chemical reaction, and results in a purple color which is 
read as negative (white), trace (slightly purple), + (light purple), or ++ (dark purple). The 
samples were applied directly to the strips and results were read after a minute. The use of these 
test trips enables results to be available rapidly and within the clinic setting. Table VI dis-plays 
the results obtained when ++ or + was deemed positive.  
Expansion of this data set is part of current research efforts at our institution. Presently, 
the LE strip test boasts high sensitivity and specificity for diagnosis of PJI. Our results approach 
and even exceed those of several standard tests that are currently implemented (7, 9). 
Additionally, this data is was investigated for any correlation with typical serology findings 
associated with PJI such as ESR, CRP, fluid WBC, and polymorphonuclear leukocyte counts 
(PMN). Strongest correlation was found with PMN % (r=0.7769), as expected (35).  
The ease, speed, and relative low-cost of the LE strip test make it very desirable as an 
adjunct molecular diagnostic tool for orthopedic surgeons. While the final role of this leukocyte 
esterase test is to be determined, the high PPV of a ++ result (strongly positive) and the high 
NPV of a negative/trace result (negative) indicate its value as a diagnostic tool which can serve 
to increase preoperative planning because of a clear diagnosis. Future directions for this study 
aim to expand the cohort, decrease reader bias using electronic readers, and investigate ways to 
include samples that are contaminated with blood which can currently skew results of this 
colorimetric test. Improvement in these areas would hopefully enable the use of leukocyte 
esterase to be utilized in the diagnosis of PJI. 
 
 
MISSING THE MARK: CULTURE-NEGATIVE INFECTIONS 
It is important to mention a specific subset of patients diagnosed with PJI at our institution who 
lack a positive culture result. Without a causative organism, a significant road block is created 
not only in the surgical planning but also in the choice of anti-infective agent used by the 
surgeon. Even though there is a significant success rate associated with current treatments like 
irrigation and debridement (I&D), two-stage or one-stage revision, these cases must be 
considered in order to determine the best treatment plan. A review of 651 cases of PJI treated at 
our institution between 1999 and 2007 revealed 48 cases of PJI that were culture- negative. 
These cases were compared to culture-positive cases treated during the same time frame. 
Surgical intervention for these 48 cases included: I&D (13), one-stage exchange arthroplasty (3), 
and planned two-stage exchange arthroplasty (6) (Tab. VII). There is reason to believe that the 
most likely cause for these suboptimal results for culture-negative PJI cases stems from an 
inability to isolate a pathogen from conventional culture. This ongoing study serves to 
underscore the importance of additional efforts to identify fungi or atypical pathogens that could 
be the cause of CN PJI.  
One such effort focused on the use of a new molecular diagnostic tool called IBIS T5000 
Biosensor in an attempt to uncover a causative organism in CN cases of PJI. This technology 
utilizes pan-genomic primers in a series of polymerase chain reactions to identify known 
pathogens and virulence genes. Using mass spectrometry to asses the base composition of an 
identified region of DNA, this technology identifies specific genes, such as the mecA gene for 
methicillin resistance, giving surgeons important information about the type of pathogen isolated 
from the joint. These results, combined with the PCR results, are then compared to a database to 
match them with the closest possible microorganism (12). We prospectively collected 
intraoperative synovial fluid samples from 80 patients (65 revision total knee and 15 revision hip 
arthroplasty) and analyzed them with IBIS as well as conventional culture. The surgeon 
determined 23 of the cases to be infected and 57 as uninfected or aseptic revisions. Eighteen of 
the 23 infected cases were culture-positive, and IBIS isolated the same organism in 17 of these 
cases. Though the remaining 5 infected cases were culture negative, IBIS isolated an organism in 
4 of them. Furthermore, IBIS found a pathogen in 50 of the 57 aseptic revision cases. If one uses 
a positive culture to indicate infection, then 87.7% of the so-called aseptic revisions may indeed 
be missed infections. Due to its increased sensitivity compared to culture, we believe that IBIS 
may be of great value in isolating a microorganism in specifc cases with either negative cultures 
or abnormal serology and/or cell count. Furthermore, by providing a plethora of information, 
such as the discovery of new genes and mutations within species, IBIS can help to better 
understand the diagnosis of treatment of patients with PJI. 
 
CONCLUSIONS 
Periprosthetic joint infection compromises the results of total joint arthroplasty, which 
historically has been a highly successful operation. The work investigating the molecular 
markers discussed in this paper aims to narrow the focus of future research in the diagnosis and 
treatment of PJI. Future research on PJI aims to combat current diagnostic  
challenges through the development of an accurate and efficient tool. The primary goal is one 
marker with high sensitivity and specificity. Ongoing studies aim to expand the cohort in cases 
with C-reactive protein and leukocyte esterase analysis. Results thus far give promise that 
molecular markers can facilitate diagnosis of PJI as they may serve as a future gold standard 
modality that is rapid, inexpensive, and highly accurate. 
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